Teladoc Health (NYSE:TDOC) Announces Quarterly Earnings Results

Teladoc Health (NYSE:TDOC) announced its quarterly earnings results on Wednesday. The health services provider reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05, FiscalAI reports. The firm had revenue of $642.27 million during the quarter, compared to analysts’ expectations of $635.33 million. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. Teladoc Health updated its Q1 2026 guidance to -0.450–0.350 EPS and its FY 2026 guidance to -1.100–0.700 EPS.

Teladoc Health Price Performance

TDOC traded up $0.12 on Wednesday, reaching $4.66. The company had a trading volume of 6,087,236 shares, compared to its average volume of 6,532,484. Teladoc Health has a one year low of $4.40 and a one year high of $11.55. The company has a market capitalization of $826.12 million, a P/E ratio of -3.64 and a beta of 2.12. The company has a fifty day moving average of $6.11 and a 200-day moving average of $7.24. The company has a current ratio of 2.70, a quick ratio of 2.60 and a debt-to-equity ratio of 0.71.

Analyst Upgrades and Downgrades

TDOC has been the subject of a number of recent analyst reports. Barclays began coverage on shares of Teladoc Health in a report on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price target for the company. BMO Capital Markets assumed coverage on shares of Teladoc Health in a research report on Thursday, November 13th. They set a “market perform” rating and a $8.00 price target for the company. Zacks Research lowered shares of Teladoc Health from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Finally, Evercore lowered their price objective on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating for the company in a report on Thursday, October 30th. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $9.12.

Insider Transactions at Teladoc Health

In related news, insider Adam C. Vandervoort sold 5,720 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $42,842.80. Following the completion of the transaction, the insider owned 80,732 shares of the company’s stock, valued at $604,682.68. This trade represents a 6.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Charles Divita III sold 17,138 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the sale, the chief executive officer directly owned 201,036 shares of the company’s stock, valued at $1,533,904.68. The trade was a 7.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 33,288 shares of company stock worth $251,684 in the last three months. 0.58% of the stock is currently owned by company insiders.

Institutional Trading of Teladoc Health

A number of large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP increased its holdings in shares of Teladoc Health by 23.8% in the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after buying an additional 1,325,106 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Teladoc Health during the 4th quarter worth $9,156,000. Bridgeway Capital Management LLC purchased a new stake in Teladoc Health during the second quarter valued at about $8,729,000. Man Group plc boosted its holdings in shares of Teladoc Health by 113.8% in the fourth quarter. Man Group plc now owns 1,620,633 shares of the health services provider’s stock worth $11,344,000 after buying an additional 862,454 shares during the period. Finally, Nuveen LLC lifted its position in shares of Teladoc Health by 38.7% in the 4th quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider’s stock valued at $18,618,000 after acquiring an additional 742,240 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.